METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Clinical trials for METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New oral drug trial aims to boost cancer treatment for Tough-to-Treat breast cancer
Disease control Recruiting nowThis early-stage trial is testing the safety and best dose of a new oral drug called ASTX727 when given alongside standard chemotherapy (paclitaxel) and immunotherapy (pembrolizumab) for metastatic triple-negative breast cancer. The study aims to see if adding ASTX727 can help sh…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 02, 2026 14:58 UTC
-
Custom cancer vaccine designed to train your own immune system
Disease control Recruiting nowThis study is testing a new, personalized vaccine designed to teach the body's immune system to recognize and attack a patient's specific cancer. It is being given alongside an existing immunotherapy drug (pembrolizumab) to adults with advanced solid tumors that have spread. The …
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 02, 2026 14:58 UTC
-
Scientists test novel drug duo in fight against Tough-to-Treat cancers
Disease control Recruiting nowThis early-phase study aims to find a safe and tolerable dose of a new drug combination for people with advanced breast cancer and other solid tumors that have a protein called HER2. The trial will test pidnarulex, which aims to stop tumor cell growth, together with an existing t…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New vaccine trial aims to train immune system to fight breast cancer in the brain
Disease control Recruiting nowThis study is testing a two-part treatment for breast cancer that has spread to the brain. Patients receive a personalized vaccine made from their own immune cells, combined with an immunotherapy drug called pembrolizumab. The goal is to see if this combination can shrink brain t…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Scientists test Custom-Made vaccine to fight spreading breast cancer
Disease control Recruiting nowThis study is testing whether adding a personalized vaccine to standard immunotherapy and chemotherapy helps control advanced triple-negative breast cancer that has spread. It will compare two groups of about 70 patients total: one gets the vaccine plus standard drugs, the other …
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Can a smartphone app help cancer patients live better and stay out of the hospital?
Disease control Recruiting nowThis study is testing whether adding a digital health app to standard cancer care helps patients with advanced triple-negative breast cancer. About 472 patients starting their first treatment will either use the app to report symptoms and get advice or receive standard care alone…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: NA • Sponsor: UNICANCER • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New hope for Tough-to-Treat breast cancer: old drugs, new combo
Disease control Recruiting nowThis study is testing whether combining two existing drugs—tamoxifen and a special form of doxorubicin—can help control advanced triple-negative breast cancer that has spread or cannot be removed by surgery. It is for patients whose cancer has continued to grow despite at least t…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Doctors test custom cancer vaccine to train immune system
Disease control Recruiting nowThis early-stage trial is testing a new, personalized vaccine for triple-negative breast cancer (TNBC). The vaccine is custom-made from a piece of a patient's own tumor and is designed to teach their immune system to recognize and attack the cancer. Researchers are studying the v…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New vaccine trial aims to train immune system to fight aggressive breast cancer
Disease control Recruiting nowThis study is testing whether a new vaccine called STEMVAC, when given alongside standard chemotherapy, can help control advanced triple-negative breast cancer. The vaccine is designed to teach the body's immune system to recognize and attack cancer cells. Researchers will enroll…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Scientists test Triple-Threat attack on tough breast cancer
Disease control Recruiting nowThis early-stage trial is testing the safety of a new three-drug combination for people with advanced triple-negative breast cancer. It combines a new experimental pill (ZEN003694) with an immunotherapy drug (pembrolizumab) and a standard chemotherapy (nab-paclitaxel). The main g…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Common drug ivermectin tested in new fight against aggressive breast cancer
Disease control Recruiting nowThis early-stage study is testing whether adding the drug ivermectin to standard immunotherapy helps shrink tumors in people with advanced triple-negative breast cancer that has spread. The main goals are to find a safe dose and see if the combination is more effective than immun…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Yuan Yuan • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
New drug duo targets aggressive breast Cancer's weak spots
Disease control Recruiting nowThis early-stage trial is testing the safety and effectiveness of combining two drugs, neratinib and ruxolitinib, for a difficult-to-treat form of breast cancer. It is for people whose triple-negative breast cancer has spread and returned to the chest wall after previous chemothe…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
Tracking promising cancer drugs in real patients
Knowledge-focused Recruiting nowThis study aims to collect real-world information about how well FDA-approved antibody-drug conjugate (ADC) treatments work for people with advanced HER2-negative breast cancer. Researchers will follow 100 patients receiving these treatments as part of their regular care to under…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Mar 18, 2026 14:41 UTC